Steven Eschrich

Professor

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (24)

Background: Epigenetic changes associated with human papillomavirus (HPV)–driven tumors have been described; however, HPV type–specific alterations are less well understood. We sought to compare HPV16-specific methylation changes with those in virus-unassociated head and neck squamous cell carcinomas (HNSCC). Methods: Within The Cancer Genome Atlas, 59 HPV16 + HNSCC, 238 nonviral HNSCC (no detectable HPV or other viruses), and 50 normal head and neck tissues were evaluated. Significant differentially methylated regions (DMR) were selected, and key associated genes were identified. Partial least squares models were generated to predict HPV16 status in additional independent samples. Results: HPV infection in HNSCC is associated with type-specific methylomic profiles. Multiple significant DMRs were identified between HPV16 + , nonviral, and normal samples. The most significant differentially methylated genes, SYCP2, MSX2, HLTF, PITX2 , and GRAMD4 , demonstrated HPV16-associated methylation patterns with corresponding alterations in gene expression. Phylogenetically related HPV types (alpha-9 species; HPV31, HPV33, and HPV35) demonstrated a similar methylation profile to that of HPV16 but differed from those seen in other types, such as HPV18 and 45 (alpha-7). Conclusions: HNSCC linked to HPV16 and types from the same alpha species are associated with a distinct methylation profile. This HPV16-associated methylation pattern is also detected in cervical cancer and testicular germ cell tumors. We present insights into both shared and unique methylation alterations associated with HPV16 + tumors and may have implications for understanding the clinical behavior of HPV-associated HNSCC. Impact: HPV type–specific methylomic changes may contribute to understanding biologic mechanisms underlying differences in clinical behavior among different HPV + and HPV − HNSCC.

Year:

2025

TNBC is most common in the NHB cohort. A, Stacked bar chart showing the fraction of patients with each level of HER2 expression among the four cohorts ( P = 0.387, χ 2 test). B, Stacked bar chart showing that the HR−/HER2− (triple-negative) phenotype is more frequent in the cores from the NHB patients ( P = 0.004, Fisher exact test). HR, hormone receptor (ER and PR); PPN, percent positive nuclei.

Year:

2025

High expression of the proliferative marker Ki-67 is more frequent among cores from the NHB cohort. A, Boxplots comparing Ki-67% positivity as a function of the cohort. B, Risk categories for Ki-67 (low risk, 14 PPN) are shown as stacked bar charts. Supplementary Table S13 tabulates these data (see rows Ki-67 PPN and Ki-67 risk category). PPN, percent positive nuclei.

Year:

2025

Breast cancer is a leading cause of cancer-related mortality among women worldwide and is known to have higher mortality among women with African ancestry. Herein, we describe the creation and characterization of a multiethnic breast cancer tissue microarray (ME-BrTMA) representing tumors from non-Hispanic White ( n = 41), non-Hispanic Black (NHB; n = 45), and Hispanic patients from Puerto Rico ( n = 36) and Florida ( n = 52). This ME-BrTMA comprises five blocks with a total of 610 cores: 371 breast cancer tumor cores, 93 breast stromal cores, 96 normal breast tissue cores, 30 non–breast cancer tumor cores, and 20 cores representing normal tissues. Initial characterization of the ME-BrTMA includes standard IHC staining of well-characterized clinical biomarkers, including the estrogen hormone receptors and progesterone hormone receptors, HER2, and Ki-67, interpreted by the coauthoring pathologist (Marilin Rosa). The IHC results indicated good but imperfect alignment with clinical diagnoses. Cores from breast cancer tumors from the NHB cohort most frequently scored negative for estrogen receptor (63%, P P P P Significance: The ME-BrTMA described herein provides a resource that may serve as a tool to understand the underlying biology of breast cancer.

Year:

2025

PAM50 analysis shows that basal-like subtype is most frequent among NHBs. Stacked bar chart shows the results of PAM50 gene expression analysis on patients represented on the ME-BrTMA with available RNA sequencing data. The data show that the basal-like subtype is most frequent among NHBs represented on the TMA ( P = 0.031). Supplementary Table S15 tabulates the PAM50 subgroup breakdown by cohort. Note that RNA sequencing data for the NHW patients in cohort 1 are not included because they are not available.

Year:

2025

The frequency of ER-negative and PR-negative expression is highest in tumor cores from patients in the NHB cohort. A, Stacked bar chart showing that the frequency of negative ER expression is highest in cores from the NHB cohort (Fisher exact test, P = 0.001). B, Stacked bar chart showing that the frequency of PR-negative expression is highest in cores from the NHB cohort (χ 2 test, P = 0.003). C, Stacked bar chart showing that the frequency of HR-negative expression is highest in cores from the NHB cohort (χ 2 test, P = 0.006, χ 2 test). PPN, percent positive nuclei.

Year:

2025

Metadata of the brain and extracranial melanoma metastases (Visium), and Merkel Cell Carcinoma (CosMx) samples used in the spatialGE analyses. The file also contains the accession numbers and links to the data used in this work.

Year:

2025

Impact of surgery vs. biopsy sample on signature scores. A, Breast cancer specimens from tissue resection (surgery) and punch biopsy (biopsy) were compared. B, Head and neck cancer specimens from tissue resection (surgery) and punch biopsy (biopsy) were compared.

Year:

2025

Proficiency and repeatability of the CLIA laboratory in generating 12CK GES and RSI. A, Proficiency of the CLIA laboratory compared with an established research-grade molecular genomics shared resource facility. Four samples were previously processed by the MCC Molecular Genomics Core (MGC) and available for CLIA laboratory processing. GESs were derived from both experimental conditions. The experiment was performed to determine that the CLIA laboratory was proficient in generating the expression data for the HG-U133Plus platform. Left, 12CK GES scores in MGC vs. CLIA laboratory ( r = 0.991) indicating high correlation, although signature calibration was needed. Right, RSI signature scores in MGC vs. CLIA laboratory indicating compressed RSI signal from the CLIA experiments. B, Repeatability of GES from quadruplicate samples in the CLIA laboratory. Four samples were processed in quadruplicate and arrayed in the CLIA laboratory from the same operator. GES scores were derived from each experiment. Left, 12CK GES scores had a low variability in each of the four samples. Right, RSI was identical in two samples and had low level of variability in two samples.

Year:

2025

Experimental design of CLIA validation experiments. The experiments were organized into three categories: accuracy, precision, and sample content. Each of these categories assessed different sources of variability expected to impact signature scores

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (18)

Jong Park

Professor

-

UNITED STATES
View details

Seung Joon Kim

-

SOUTH KOREA
View details

Javier Torres-Roca

Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Idhaliz Flores

Professor

Ponce Health Sciences University

UNITED STATES
View details

William D Cress

Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Anders Berglund

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

José Antonio Oliveras Torres

Assistant Professor / Puerto Rico BioBank Co-leader

Ponce Health Sciences University

UNITED STATES
View details

Harold I Saavedra

Professor

Ponce Health Sciences University

UNITED STATES
View details

Niki Zacharias Millward

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Timothy Shaw

Assistant Member/Professor

Moffitt Cancer Center

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Silvia Regina Rogatto

University of Southern Denmark

DENMARK
View details

Inna Smalley

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paulo Rodriguez

Senior Member-Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Xiaoqing Yu

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Dung-Tsa Chen

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Kenneth Tsai

Vice Chair of Research, Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paul Stewart

Research Associate Professor

University of Utah

UNITED STATES
View details